Ben Bikman
Dr. Ben Bikman is a metabolic health specialist who focuses on metabolic dysfunction and insulin resistance. His work examines how lifestyle factors such as diet, exercise, and sleep influence metabolic health and can help reverse insulin resistance. He also evaluates the use and impact of weight loss medications, including Ozempic and other GLP-1 agonists.
96 claims checked on air: 17 context 13 contradicted 9 overstated 48 supported 9 unverified
What they said on air - supported
Acanthosis nigricans and skin tags are strong clinical physical indicators of insulin resistance.
"One of them is a condition called acanthosis nigricans... And then the other one people know is called skin tags... Both of those are very, very strong evidence of insulin resistance." (said at 0:07:07)
Extensive clinical and observational literature supports that both acanthosis nigricans and multiple skin tags (acrochordons) are well-recognized physical cutaneous indicators of hyperinsulinemia and insulin resistance. Mechanistically, elevated circulating insulin levels stimulate keratinocyte and fibroblast proliferation directly and via insulin-like growth factor-1 (IGF-1) receptors, leading to these epidermal changes. Acanthosis nigricans exhibits high specificity for insulin resistance, while multiple skin tags frequently serve as an early, sensitive physical marker prompting metabolic evaluation.
Insulin directly affects every single cell in the human body.
"Insulin is one of the few peptide hormones that will literally affect every single cell of the body from brain cells to bone cells, lung cells to liver cells, and every cell in between. There's no exception. Insulin will have an effect at every cell of the body." (said at 0:11:26)
Published endocrinological literature confirms that insulin receptors are ubiquitously expressed across virtually all cell types in the human body—spanning classic metabolic target tissues (liver, skeletal muscle, adipose tissue) as well as non-classical targets including neurons, osteocytes, pulmonary cells, and immune cells. In addition to regulating cellular metabolism and glucose handling, insulin functions broadly as a growth and survival factor with mitogenic and signaling effects across cell types throughout the body.
In erectile dysfunction associated with insulin resistance, insulin's ability to produce nitric oxide in endothelial vessels is impaired, causing reduced vasodilation.
"Like in the case of erectile dysfunction, insulin is less capable at producing nitric oxide in the endothelium of the blood vessels. So there's less vasodilation. Less vasodilation means compromised erectile function." (said at 0:11:47)
Under normal physiological conditions, insulin stimulates endothelial nitric oxide synthase (eNOS) activation primarily via the PI3K/Akt signaling pathway, producing nitric oxide (NO) and promoting vascular relaxation. In states of insulin resistance, this pathway is selectively impaired, blunting insulin-stimulated NO production and endothelium-dependent vasodilation. In the penile vasculature, this endothelial dysfunction reduces the vasodilatory capacity essential for penile erection, directly contributing to erectile dysfunction.
Elevated stress hormones such as cortisol and epinephrine cause acute insulin resistance in humans within hours.
"And that is stress. So elevated stress hormones, whether it's cortisol or epinephrine/adrenaline, will cause acute insulin resistance in humans. As that stimulus goes away, the problem resolves." (said at 0:13:31)
Human experimental studies using hyperinsulinemic-euglycemic clamps demonstrate that acute elevations of stress hormones, such as epinephrine (adrenaline) and glucocorticoids, cause rapid insulin resistance within hours. Regional intra-arterial perfusion of adrenaline directly inhibits insulin-stimulated glucose uptake in human skeletal muscle within three hours. Furthermore, acute infusion of counter-regulatory stress hormones (epinephrine, hydrocortisone, glucagon, and growth hormone) simulating acute stress produces an 88% reduction in the insulin sensitivity index.
Elevated inflammatory cytokines cause rapid insulin resistance in humans, rodents, and cell cultures.
"Next is inflammation. If you increase the levels of inflammatory cytokines in cells or rodents or humans, they will be insulin resistant very quickly." (said at 0:13:41)
Experimental studies in humans, rodents, and cell cultures demonstrate that acute administration of proinflammatory cytokines (such as TNF-alpha) rapidly induces insulin resistance. In healthy human volunteers, short-term infusion of TNF-alpha significantly increases homeostasis model assessment of insulin resistance (HOMA-IR) and impairs peripheral insulin sensitivity. In rodent models, acute 3-hour TNF-alpha infusions impair insulin-mediated muscle glucose uptake by over 50%. In cultured muscle cells, TNF-alpha exposure impairs insulin receptor substrate signaling and inhibits glucose uptake.
High levels of insulin itself directly cause insulin resistance in humans, rodents, and cell cultures.
"And then lastly of the primary fast causes of insulin resistance is too much insulin itself. So we know in humans, rodents, and cells—I've published my own work on this topic—that too much insulin will result in a resistance to the stimulus. So too much insulin can cause insulin resistance." (said at 0:14:04)
Experimental evidence in humans, animal models, and in vitro cell cultures demonstrates that sustained hyperinsulinemia directly induces insulin resistance. In controlled human metabolic studies, continuous hyperinsulinemic infusions over extended periods (e.g., 40 hours) significantly reduce subsequent insulin-stimulated glucose utilization and whole-body glucose disposal compared to controls, demonstrating that elevated insulin levels themselves directly induce peripheral insulin resistance via post-receptor desensitization and signaling downregulation.
- supports: Production of insulin resistance by hyperinsulinaemia in man. (Diabetologia 1985) · cited 297x in the literature
"After 40 h of hyperinsulinaemia, glucose utilization and overall glucose metabolism at submaximally and maximally effective plasma insulin concentrations were both slightly, but significantly, reduced compared with values observed after the infusion of saline (p less than 0.05)... These results indicate that hyperinsulinaemia of the magnitude observed in insulin resistant states, such as obesity, can produce insulin resistance in man." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Bret Goodpaster and David Kelley demonstrated that lean, highly insulin-sensitive endurance athletes have intramuscular triglyceride levels as high as obese individuals with type 2 diabetes.
"Bret Goodpaster and David Kelley 30 years ago described this phenomenon of the athletes paradox, where they noted that in obesity with type 2 diabetes and insulin resistance, if you pull a muscle biopsy, there's really high levels of fat in the muscle of triglycerides, and they're very insulin resistant... And yet when they did muscle biopsies from very lean, exceptionally insulin-sensitive marathon runners, they had just as much fat in their muscle in the form of triglycerides as the obese type 2 diabetics did." (said at 0:14:40)
Bret Goodpaster, David Kelley, and colleagues formally described the 'athlete's paradox' in a 2001 physiological study comparing lean trained endurance athletes, sedentary lean individuals, obese individuals, and obese patients with type 2 diabetes. Using percutaneous vastus lateralis muscle biopsies and hyperinsulinemic-euglycemic clamps, they demonstrated that endurance-trained athletes had high insulin sensitivity alongside elevated intramyocellular lipid levels (2.36 ± 0.37% lipid area) comparable to those observed in insulin-resistant obese individuals and patients with type 2 diabetes (3.04 ± 0.39% lipid area).
- supports: Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-… (The Journal of clinical endocrinology and metabolism 2001) · cited 1147x in the literature
"Insulin sensitivity (M) determined during a hyperinsulinemic (40 mU x m(-2)min(-1)) euglycemic clamp was greater (P < 0.01) in L and T, compared with O and D (9.45 +/- 0.59 and 10.26 +/- 0.78 vs. 5.51 +/- 0.61 and 1.15 +/- 0.83 mg x min(-1)kg fat free mass(-1), respectively). IMCL in percutaneous vastus lateralis biopsy specimens by quantitative image analysis of Oil Red O staining was approximately 2-fold higher in D than in L (3.04 +/- 0.39 vs. 1.40 +/- 0.28% area as lipid; P < 0.01). IMCL was also higher in T (2.36 +/- 0.37), compared with L (P < 0.01)... In summary, skeletal muscle of trained endurance athletes is markedly insulin sensitive and has a high oxidative capacity, despite having an elevated lipid content." (abstract, results, passage verified)
pubmedfull study (doi)
Ceramides directly block insulin signaling by inhibiting Akt phosphorylation.
"When insulin binds to its receptor, then you have a series of phosphorylation events. Ceramides block that very well. It's a very well-defined pathway. And if you can just do one thing and just resolve the ceramides, you correct the insulin signaling." (said at 0:15:47)
Extensive mechanistic research in cell culture and animal models confirms that ceramide accumulation impairs insulin signaling by inhibiting Akt/PKB activation and phosphorylation. Ceramides inhibit Akt through two main established pathways: activating atypical protein kinase C (PKC-zeta), which phosphorylates the Akt pleckstrin homology domain and prevents its translocation to the plasma membrane, and activating protein phosphatase 2A (PP2A), which directly dephosphorylates Akt. While other lipid intermediates (such as diacylglycerols) also contribute to overall insulin resistance, the specific pathway by which ceramides block insulin-stimulated Akt activation is well defined.
- supports: Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein … (Molecular and cellular biology 2003) · cited 352x in the literature
"Under these circumstances, ceramide activated PKCzeta, leading to phosphorylation of the PKB-PH domain on Thr(34). This phosphorylation inhibited phosphatidylinositol 3,4,5-trisphosphate (PIP(3)) binding to PKB, thereby preventing activation of the kinase by insulin." (abstract, passage verified)
pubmedfull study (doi) - supports: Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to… (The Journal of biological chemistry 2004) · cited 394x in the literature
"The sphingolipid ceramide negatively regulates insulin action by inhibiting Akt/protein kinase B (PKB), a serine/threonine kinase that is a central regulator of glucose uptake and anabolic metabolism... ceramide blocks insulin stimulation of Akt/PKB by two independent mechanisms. First, using the isolated pleckstrin homology domain, we found that ceramide specifically blocks the translocation of Akt/PKB, but not its upstream activator phosphoinositide-dependent kinase-1, to the plasma membrane. Second, using a construct lacking this pleckstrin homology domain, which does not require translocation for activation, we found that ceramide stimulates the dephosphorylation of Akt/PKB by protein phosphatase 2A." (abstract, passage verified)
pubmedfull study (doi) - supports: Characterising the inhibitory actions of ceramide upon insulin signaling in different skel… (PloS one 2014) · cited 59x in the literature
"Depending on cell type, these lipid intermediates have been shown to inhibit protein kinase B (PKB/Akt), a key mediator of the metabolic actions of insulin, via two distinct pathways: one involving the action of atypical protein kinase C (aPKC) isoforms, and the second dependent on protein phosphatase-2A (PP2A)." (abstract, passage verified)
pubmedfull study (doi)
George Cahill fasted human subjects for multiple days and administered insulin to drop blood glucose to approximately 20 mg/dL while they remained conscious.
"In fact, Dr. George Cahill did these studies about 40 years ago; you could never get IRB approval to do it now—he would fast men for days and then give them an insulin dose and drive their glucose levels down to about 20 milligrams per deciliter, just to see how low could the glucose get and the person maintains consciousness. And they did." (said at 0:23:39)
The speaker accurately describes classic metabolic research demonstrating that after prolonged fasting, human subjects given insulin challenges remain conscious and asymptomatic despite severe hypoglycemia. Landmark work by George Cahill's group established that ketones replace glucose as the primary fuel for the brain during starvation (Owen et al., 1967), and Drenick et al. (1972) specifically administered insulin to men fasted for two months, driving blood glucose down to levels as low as 0.5 mmol/L (9 mg/dL)—well below 20 mg/dL—without precipitating hypoglycemic reactions or loss of consciousness.
In cell culture models, treating cells with the saturated fat palmitate causes insulin resistance via conversion into ceramides, whereas treatment with monounsaturated or polyunsaturated fatty acids does not.
"in cell cultures, if you treat cells with saturated fat, palmitate, which is the main saturated fat in the body, you get insulin resistance very quickly. Now, if you block ceramides, you resolve that insulin resistance. If you treat those cells with monounsaturated fatty acid, no insulin resistance. If you treat those cells with polyunsaturated fatty acid, no insulin resistance." (said at 0:29:16)
In vitro cell culture studies in skeletal muscle cells (such as C2C12 myotubes and human myotubes) demonstrate that exposure to the saturated fatty acid palmitate causes insulin resistance by promoting de novo synthesis of ceramides, which impairs Akt/PKB activation and insulin-stimulated glucose metabolism. Inhibiting ceramide synthesis prevents or restores insulin signaling following palmitate treatment. In contrast, monounsaturated fatty acids such as oleate do not induce ceramide accumulation or impair Akt activation. Because the claim specifies effects in cell culture models, it is supported by in vitro literature, though certainty is rated very low due to the purely cell-culture nature of the evidence.
- supports: Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and … (Archives of biochemistry and biophysics 2003) · cited 505x in the literature
"In C2C12 myotubes, palmitate, but not oleate, inhibited insulin-stimulation of glycogen synthesis, as well as its activation of Akt/Protein Kinase B (PKB), an obligate intermediate in the regulation of anabolic metabolism. Palmitate also induced the accrual of ceramide" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are r… (Journal of cellular physiology 2007) · cited 71x in the literature
"blocking ceramide production abolished the palmitate-induced reduction in signalling, suggesting that ceramide synthesis is critical for palmitate's actions. Oleate did not effect pAKT" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insuli… (American journal of physiology. Endocrinology and metabolism 2010) · cited 284x in the literature
"Blocking de novo synthesis of ceramide abolished the effects of palmitate on mtROS production, viability, and insulin signaling." (abstract, results, passage verified)
pubmedfull study (doi)
Co-incubating cells with oleic acid or linoleic acid reverses palmitate-induced insulin resistance.
"we would treat cells with palmitate, cause insulin resistance, co-treat them, co-incubate the cells with either oleic acid or linoleic acid, and we would reverse the insulin resistance." (said at 0:30:27)
The claim accurately describes in vitro cell culture findings. In skeletal muscle cells (such as cultured rat and human myotubes) and other cell models, palmitate (a saturated fatty acid) induces insulin resistance, whereas co-treatment or pre-incubation with unsaturated fatty acids—specifically monounsaturated fatty acids like oleic acid or polyunsaturated fatty acids like linoleic acid—blocks or reverses palmitate-induced impairments in insulin signaling (e.g., Akt phosphorylation). Because this is based strictly on in vitro cell culture models, the GRADE certainty is very low.
All dietary animal sources of fat contain some amount of linoleic acid.
"literally any animal source of fat, any animal food has some linoleic acid in it. It's ubiquitous." (said at 0:30:53)
Linoleic acid (an essential 18-carbon omega-6 polyunsaturated fatty acid) is ubiquitous across dietary animal fats, including beef tallow, lard, poultry fat, dairy fat, eggs, and seafood. Because animals obtain linoleic acid through their diets (from plants, grains, or forage) and incorporate it into cellular membranes and adipose triglycerides, all animal lipid sources naturally contain varying proportions of linoleic acid.
When carbohydrate intake is reduced, humans can consume two to four times more saturated fat while maintaining significantly lower circulating plasma saturated fat levels.
"you can have humans that if the carbohydrate levels are going down, they can eat two or three or four times more saturated fat than a high-carb group. And then their circulating levels of saturated fat, so the saturated fat in the plasma, is significantly lower." (said at 0:31:40)
Randomized controlled feeding trials demonstrate that when dietary carbohydrate intake is restricted, individuals consuming substantially higher levels of saturated fatty acids (e.g., doubling or tripling intake) exhibit stable or reduced levels of circulating saturated fatty acids and palmitoleic acid (a marker of de novo lipogenesis) compared to baseline or low-fat, high-carbohydrate diets.
Medium-chain triglycerides (MCTs) do not serve as substrates for ceramide synthesis.
"which is not a substrate for ceramides. So, it doesn't quite fit." (said at 0:36:00)
The rate-limiting initial step of de novo sphingolipid and ceramide biosynthesis is catalyzed by serine palmitoyltransferase (SPT), which conjugates L-serine with long-chain fatty acyl-CoAs—predominantly palmitoyl-CoA (C16), and to a lesser extent other long-chain acyl-CoAs ranging from C14 to C18. Medium-chain fatty acids/triglycerides (MCTs, typically C6–C12) do not serve as substrates for SPT or the de novo ceramide synthesis pathway.
In Kevin Hall's 2021 ad libitum feeding study, subjects on a plant-based high-carbohydrate diet spontaneously consumed approximately 700 fewer calories per day than those on a ketogenic diet.
"they found that the higher-carb group spontaneously ate about 700 calories a day less." (said at 0:39:01)
In a 2021 randomized crossover inpatient feeding trial led by Kevin D. Hall, 20 adults consumed either a plant-based, low-fat, high-carbohydrate diet (75.2% carbohydrate) or an animal-based, ketogenic, low-carbohydrate diet (10.0% carbohydrate) ad libitum for two weeks before switching to the alternate diet. Participants spontaneously consumed an average of 689 ± 73 kcal per day less on the high-carbohydrate, low-fat diet than on the ketogenic diet across the two-week period (and 544 ± 68 kcal/day less during the final week), matching the claim of approximately 700 calories per day less.
A study by Nair and colleagues demonstrated that insulin administration in type 1 diabetes begins to reduce the elevated metabolic rate within minutes.
"a group at Minnesota, the first author is Nair, N-A-I-R, they not only confirmed the findings from 60 or 70 years earlier that in type 1 diabetes the metabolic rate is too high, like something's broken, they're burning too hot, but when you gave them insulin, within minutes the metabolic rate began to slow down." (said at 0:43:02)
Research by K. Sreekumaran Nair and colleagues established that poorly controlled or insulin-deprived type 1 diabetes is characterized by an elevated basal/resting metabolic rate and increased catabolism, confirming early metabolic observations. Their interventional physiology studies demonstrated that acute intravenous insulin replacement rapidly suppresses protein breakdown and reduces elevated energy expenditure/resting metabolic rate back toward baseline levels.
Human studies on time-restricted eating comparing a breakfast-plus-lunch feeding window to a lunch-plus-supper window show superior metabolic outcomes when meals are eaten earlier in the day.
"studies that have looked at humans finding where they do the kind of intermittent fasting or time-restricted eating of you have one group eat breakfast and lunch, one group eat lunch and supper, the lunch and supper group has worse outcomes. Not that they're not better. I mean, any one of those is better than the standard, but when you compare the two, the outcomes are better for the meals being earlier in the day." (said at 0:55:41)
Randomized trials and systematic reviews/network meta-analyses directly comparing early time-restricted eating (eTRE, e.g., breakfast and lunch window ending late afternoon) to late time-restricted eating (lTRE, e.g., lunch and dinner window ending in the evening) show that both forms of TRE generally improve metabolic markers compared to unrestricted usual diets, but eTRE yields superior outcomes on key cardiometabolic indices, particularly glycemic control, fasting glucose, fasting insulin, and body fat reduction.
A systematic review and network meta-analysis of randomized controlled trials (PMID: 41586347) directly comparing early TRE to late TRE found that eTRE significantly reduced body weight (mean difference -1.15 kg, 95% CI -1.86 to -0.45) and fasting insulin (-3.32 μIU/mL, 95% CI -5.36 to -1.28) compared to lTRE with high certainty of evidence, and consistently ranked highest across glycemic and anthropometric parameters. Individual 3-month randomized controlled trials (PMID: 40250088, PMID: 40731289) also found that eTRE combined with energy restriction led to greater reductions in body fat mass, fasting glucose, and leptin levels compared to lTRE combined with energy restriction.
- supports: Early time-restricted eating with energy restriction has a better effect on body fat mass,… (Clinical nutrition (Edinburgh, Scotland) 2025) · cited 19x in the literature
"eTRE + ER had greater improvements in fat mass (-1.2 % (95 % CI, -2.1, -0.2), p = 0.013) and fasting glucose (-0.35 mmol/L (95 % CI, -0.63, -0.06), p = 0.012) than participants in the lTRE + ER group... eTRE + ER showed a greater benefit for fasting blood glucose, certain anthropometric parameters and diastolic blood pressure compared to lTRE + ER and/or ER alone." (abstract, results and conclusions)
pubmedfull study (doi) - supports: Effects of timing and eating duration of time restricted eating on metabolic outcomes: sys… (BMJ medicine 2026) · cited 7x in the literature
"Time restricted eating overall improved metabolic health outcomes compared with usual diets, and early time restricted eating was superior to late time restricted eating... Compared with late time restricted eating, early time restricted eating significantly reduced body weight (mean difference -1.15 kg, 95% confidence interval -1.86 to -0.45) and fasting insulin concentrations (-3.32 μIU/ml, -5.36 to -1.28; 1 μIU/mL=6.95 pmol/L) and the certainty of the evidence was high." (abstract, results and conclusions)
pubmedfull study (doi)
A continuous intravenous infusion of adrenaline (epinephrine) in humans produces demonstrable insulin resistance within one to two hours.
"If you do a steady little drip in a human of adrenaline, they're going to be insulin resistant with demonstrably insulin resistant within just an hour or two." (said at 1:07:50)
Human experimental studies using hyperinsulinemic-euglycemic clamps and arterial/venous perfusion techniques demonstrate that continuous infusion of adrenaline (epinephrine) rapidly induces acute insulin resistance, markedly suppressing insulin-mediated peripheral glucose uptake and stimulating lipolysis within 1 to 3 hours.
Caffeine increases epinephrine levels, which in turn causes acute insulin resistance.
"Well, more caffeine is going to increase epinephrine even more. Epinephrine causes insulin resistance." (said at 1:08:09)
Randomized controlled crossover trials in humans demonstrate that acute caffeine administration stimulates the release of catecholamines, resulting in marked increases in plasma epinephrine levels and an acute reduction in whole-body insulin sensitivity (acute insulin resistance). In hyperinsulinemic-euglycemic clamp studies, caffeine administration increased plasma epinephrine roughly fivefold and reduced insulin sensitivity by approximately 15%, an effect mediated in part by epinephrine-induced lipolysis and adrenergic inhibition of peripheral glucose uptake.
Exposure to cigarette smoke particles promotes ceramide accrual, forced mitochondrial fission, and insulin resistance.
"and we published another report looking at cigarette smoke with the cigarette smoke particles. That was purely in the context of ceramides, forced mitochondrial fission, and insulin resistance, and the cigarette smoke did all of those things." (said at 1:10:24)
The speaker accurately summarizes findings from preclinical research published by their laboratory examining the metabolic consequences of cigarette smoke and sphingolipid metabolism. In mouse and cell culture models, exposure to cigarette smoke or smoke-exposed conditioned medium promoted ceramide biosynthesis and accumulation, impaired mitochondrial respiration, and induced insulin resistance, which was prevented by inhibiting ceramide synthesis (Thatcher et al., 2014). In related mechanistic work from the same group, ceramide accrual directly triggered dynamin-related protein 1 (Drp1)-mediated mitochondrial fission and suppressed insulin signaling, with Drp1 inhibition protecting against metabolic disruption (Smith et al., 2013). Because the evidence is derived exclusively from in vitro and animal models, the GRADE certainty is very low.
- supports: Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle. (The Biochemical journal 2013) · cited 87x in the literature
"A primary observation was the rapid and dramatic division of mitochondria in ceramide-treated cells. This effect is likely to be a result of increased Drp1 (dynamin-related protein 1) action, as ceramide increased Drp1 expression and Drp1 inhibition prevented ceramide-induced mitochondrial fission... However, inhibition of mitochondrial fission via Drp1 knockdown completely protected the myotubes and fibre bundles from ceramide-induced metabolic disruption, including maintained mitochondrial respiration, reduced H2O2 levels and unaffected insulin signalling." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Ceramides mediate cigarette smoke-induced metabolic disruption in mice. (American journal of physiology. Endocrinology and metabolism 2014) · cited 34x in the literature
"In mice, daily cigarette smoke exposure and HFHS diet resulted in insulin resistance, which correlated with elevated ceramides. Although myriocin injection was protective against insulin resistance with either smoke or HFHS, it was insufficient to prevent insulin resistance with combined CS and HFHS. However, myriocin injection restored muscle mitochondrial respiration in all treatments. Ceramide inhibition prevents metabolic disruption in muscle cells with smoke exposure and may explain whole body insulin resistance and mitochondrial dysfunction in vivo." (abstract, results, passage verified)
pubmedfull study (doi)
In pair-fed animal studies, inhalation of PM2.5 diesel exhaust particles at physiological levels resulted in adipocyte hypertrophy and increased total body fat mass despite identical caloric intake.
"The newer paper that we published about a year or two ago was I think the first to find that if you just have increased diesel exhaust particles, even when we calorie-clamped these we pair-fed these animals, and the animals that were inhaling more of the diesel particles at physiological levels, like at a level that a human could be exposed to, they had much fatter fat cells. So they had much more adipocyte hypertrophy, um which accounted for a higher body fat mass even though they were eating the exact same amount of calories." (said at 1:10:36)
A 2024 study in mice evaluated exposure to diesel exhaust particles (DEPs) compared to room air, finding that DEP exposure resulted in a robust shift in adipocyte hypertrophy and changes in fat mass, accompanied by altered adipose mitochondrial bioenergetics and elevated inflammatory markers. Subsequent animal work similarly confirmed that diesel particulate matter exposure induces adipocyte hypertrophy across subcutaneous and visceral fat depots. Because the supporting evidence relies exclusively on rodent models, the grade of certainty for human health outcomes is very low.
- supports: The Effect of Diesel Exhaust Particles on Adipose Tissue Mitochondrial Function and Inflam… (International journal of molecular sciences 2024) · cited 10x in the literature
"In addition to a slight change in fat mass and a robust shift in adipocyte hypertrophy in the DEP-exposed animals, we found significant changes in adipose mitochondrial bioenergetics." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Diesel Particulate Matter (DPM)-Induced Metabolic Disruption in Mice Is Mitigated by Sodiu… (Nutrients 2025) · cited 4x in the literature
"Compared to controls, DPM-exposed mice exhibited significantly elevated oxidative stress markers (* p ≤ 0.05), systemic pro-inflammatory cytokines including TNF-α, MCP-1, IL-6, and IL-1β (* p ≤ 0.05), and adipocyte hypertrophy of both subcutaneous and visceral fat depots, supporting prior findings of DPM-induced metabolic dysfunction." (abstract, results, passage verified)
pubmedfull study (doi)
Middle-aged and older women initiating statin therapy have a 50% increased risk of developing type 2 diabetes.
"And in women, middle-aged and older women have a 50% greater risk of developing type 2 diabetes when they get on a statin." (said at 1:16:08)
In a prospective analysis of 153,840 postmenopausal women aged 50–79 years enrolled in the Women's Health Initiative (Culver et al., 2012), statin use was associated with an adjusted 48% increased hazard of incident diabetes (multivariate-adjusted HR 1.48, 95% CI 1.38–1.59), which directly aligns with the speaker's claim of a 50% increase. While broader meta-analyses across general populations typically report a smaller relative increase (~9–12%), observational cohort data specifically examining middle-aged and older postmenopausal women observed this ~50% increased relative risk.
Prescribed corticosteroids promote rapid weight gain and insulin resistance by activating the glucocorticoid stress pathway.
"So if a person has an autoimmune disease or a chronic inflammatory condition and the clinician has prescribed a corticosteroid, they're going to gain weight very, very quickly because that starts to play on that stress pathway where the more cortisol is that pathway is being activated, which is what that's doing, the more you're going to make the body insulin resistant." (said at 1:16:18)
Prescription glucocorticoids (corticosteroids) bind to glucocorticoid receptors—the primary mediators of the physiological stress hormone cortisol—and promote insulin resistance, impaired glucose uptake, increased hepatic gluconeogenesis, and central weight gain (features of iatrogenic Cushing's syndrome). Comprehensive endocrinology reviews confirm that insulin resistance and weight gain are prominent adverse metabolic effects of systemic corticosteroid therapy in inflammatory and autoimmune diseases.
- supports: Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the … (Endocrine reviews 2023) · cited 196x in the literature
"However, the side effects associated with their use, including central weight gain, hypertension, insulin resistance, type 2 diabetes (T2D), and osteoporosis, often collectively termed iatrogenic Cushing's syndrome, are associated with a significant health and economic burden." (abstract, passage verified)
pubmedfull study (doi) - supports: Hepatic Glucocorticoid Receptor Action and Glucose Homeostasis. (Endocrine reviews 2026) · cited 12x in the literature
"Chronic GC exposure, which can be a result of long-term GC pharmacotherapy and prolonged stress, however, causes undesired adverse effects that include hyperglycemia and insulin resistance." (abstract, passage verified)
pubmedfull study (doi)
In a clinical study of 11 women with newly diagnosed type 2 diabetes (average baseline HbA1c of 8.9%), 90 days of dietary lifestyle intervention reduced average HbA1c to 5.6% without medication.
"We published a clinical report. So collaborating with a local clinic in Utah, we took 11 women with newly diagnosed type 2 diabetes and their A1C was 8.9%, so very much diabetic range... And in just 90 days, their A1C went down. The average A1C was 8.9 and it went to 5.6. So no sign of diabetes whatsoever after just 90 days without a pill popped or a needle injected." (said at 1:18:08)
The speaker accurately recounts a published clinical case series of 11 women with newly diagnosed type 2 diabetes who underwent a 90-day low-carbohydrate ketogenic dietary intervention (<30 g carbs/day). Baseline HbA1c averaged 8.9% and decreased to 5.6% at 90 days alongside reductions in body weight, blood pressure, and triglycerides. Because this was a very small (n=11), uncontrolled clinical case series without a comparison group or long-term follow-up, the certainty of evidence for general efficacy is very low.
- supports: Improvement in Glycemic and Lipid Profiles in Type 2 Diabetics with a 90-Day Ketogenic Die… (Journal of diabetes research 2019) · cited 52x in the literature
"Eleven women (BMI 36.3 kg/m 2 ) who were recently diagnosed with type 2 diabetes based on HbA1c over 6.5% (8.9%) volunteered to participate in an intensive dietary intervention to limit dietary carbohydrates to under 30 grams daily for 90 days. The main outcome was to determine the degree of change in HbA1c, while secondary outcomes included body weight, blood pressure, and blood lipids. The volunteers lost significant weight (85.7 ± 3.2 kg to 76.7 ± 2.8 kg) and lowered systolic (134.0 ± 1.6 to 123.3 ± 1.1 mmHg) and diastolic (89.9 ± 1.3 to 82.6 ± 1.0 mmHg) blood pressure. HbA1c dropped to 5.6%." (abstract, results, passage verified)
pubmedfull study (doi)
Human studies show that co-ingestion of fat with protein following exercise stimulates greater muscle protein synthesis than protein ingestion alone.
"There's studies in humans to show that people work out, give them protein, they'll have a certain degree of muscle protein synthesis. If you give them protein and fat, it's even higher than it was with just the protein alone." (said at 1:20:25)
Human randomized trial evidence supports this claim. In a randomized crossover study of 10 resistance-trained young men, post-exercise ingestion of whole eggs (18 g protein plus 17 g fat) stimulated myofibrillar protein synthesis to a significantly greater extent than an isonitrogenous amount of egg whites (18 g protein with 0 g fat), despite similar overall systemic leucine availability.
Bile acids secreted from the gallbladder enhance the activity of intestinal proteolytic enzymes.
"And that's most people don't appreciate that bile, when the gallbladder from the liver releases the bile into the intestines, we always just think of that as being relevant to fat digestion, and it's critical for that, but it also enhances proteolytic enzymes. It makes the proteolytic enzymes more active, they work better." (said at 1:20:55)
Published biochemical and physiological literature supports the claim. Beyond their primary role in emulsifying dietary fats, bile salts and human bile enhance the activation of intestinal proteolytic zymogens, such as the autocatalytic conversion of trypsinogen to active trypsin (up to 55-fold in vitro), and facilitate enterokinase-mediated activation of proteases in the small intestine. Because the supporting evidence comes primarily from mechanistic in vitro assays and animal/ex vivo models, the GRADE certainty is graded as low.
- supports: Enhancement of the autocatalytic activation of trypsinogen to trypsin by bile and bile aci… (Biochimica et biophysica acta 1985) · cited 12x in the literature
"We have found that bile salts and human bile cause a significant enhancement of the autocatalytic activation of trypsinogen. This effect is dependent on the calcium ion concentration and is most marked around pH 5.4 and 7.8. An optimum concentration exists for each bile salt at which the greatest enhancement occurs. At this concentration, certain bile salts have been shown to produce activation effects of up to 55-fold. It is suggested that this activation of the autocatalytic process by bile plays an important role in protein digestion in the small intestine, since it has been shown previously that duodenal trypsin levels are abnormally low in patients with an impairment of bile secretion." (abstract, passage verified)
pubmedfull study (doi)
Acetic acid reduces hepatic gluconeogenesis and stimulates GLUT4 translocation in muscle cells via AMPK activation.
"where the acetic acid will reduce hepatic gluconeogenesis to help control glucose, which is very relevant in a person with diabetes, especially type 2... Apple cider vinegar will inhibit that, and so it helps the blood glucose by just having the liver dump less glucose into the blood. But it also stimulates—and you'd mentioned GLUT4 at the muscle... AMPK gets turned on through a series of events that moves GLUT4. Well, apple cider vinegar will do the same thing in the absence of exercise, albeit to a more modest degree." (said at 1:25:20)
Preclinical in vitro and animal studies support the claim that acetic acid activates AMP-activated protein kinase (AMPK) in both liver and skeletal muscle, resulting in increased GLUT4 expression/translocation in muscle cells and suppression of hepatic lipid/glucose metabolic pathways. Specifically, studies in L6 skeletal myotubes and diabetic rat models show that acetic acid directly induces AMPK phosphorylation, stimulates GLUT4 expression and muscle glucose uptake, and decreases hepatic lipogenic and gluconeogenic gene expression. Because the specific cellular pathway is verified in cell cultures and animal models rather than in human tissue biopsy trials, the GRADE certainty is very low.
Beta-hydroxybutyrate acts as a signaling molecule through cell-surface G-protein coupled receptors to produce anti-inflammatory and antioxidant effects.
"the ketone is unique because on one hand it's a nutrient, it's a calorie to be burned, but on the other hand it's a signaling molecule, and it is known to elicit some of its signaling like anti-inflammatory effects and antioxidant effects. Part of it is through changes elicited because of a G-protein coupled receptor where it does have a cell surface receptor that it will activate." (said at 1:28:16)
Beta-hydroxybutyrate (BHB) is well established in the scientific literature as both an oxidative metabolic fuel and an active signaling molecule. BHB functions as an endogenous agonist for cell-surface G-protein coupled receptors, particularly hydroxycarboxylic acid receptor 2 (HCAR2, also known as GPR109A), through which it modulates immune cell function and mediates anti-inflammatory effects, alongside other epigenetic and intracellular signaling mechanisms.
The brain can use lactate as an energy fuel, albeit to lower levels than glucose and ketones.
"Although the brain does use lactate as a fuel as well, albeit to lower levels." (said at 1:32:24)
Extensive physiological and biochemical research supports that the brain can utilize lactate as an oxidative energy substrate via neuronal and astrocytic lactate shuttles and blood-borne uptake during periods of elevated circulating lactate (such as intense exercise). However, glucose remains the brain's primary fuel, and ketone bodies serve as the major alternative fuel during prolonged fasting or ketogenic states, with lactate acting as a supplemental or opportunistic substrate under specific conditions.
- supports: Brain lactate metabolism: the discoveries and the controversies. (Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2012) · cited 483x in the literature
"Lactate utilization by the adult brain increases during lactate infusions and strenuous exercise that markedly increase blood lactate levels. Lactate can be an 'opportunistic', glucose-sparing substrate when present in high amounts, but most evidence supports glucose as the major fuel for normal, activated brain." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Lactate as a supplemental fuel for synaptic transmission and neuronal network oscillations… (Journal of neurochemistry 2024) · cited 46x in the literature
"Lactate shuttled from the blood circulation, astrocytes, oligodendrocytes or even activated microglia (resident macrophages) to neurons has been hypothesized to represent a major source of pyruvate compared to what is normally produced endogenously by neuronal glucose metabolism... In conclusion, lactate is less effective than glucose and potentially detrimental during neural network rhythms featuring high energetic costs" (abstract, background and conclusions, passage verified)
pubmedfull study (doi)
Palmitate directly activates TLR4 (Toll-like receptor 4), which subsequently drives the synthesis of ceramides.
"You have palmitate coming out that will directly be activating TLR4, the receptor that's going to then drive ceramides to be synthesized." (said at 1:35:25)
Preclinical and in vitro studies demonstrate that saturated fatty acids like palmitate stimulate Toll-like receptor 4 (TLR4) signaling, which upregulates key enzymes (such as serine palmitoyltransferase) required for de novo ceramide biosynthesis and contributes to lipid-induced insulin resistance. Because this mechanism is established primarily in rodent models and cultured cell lines, human clinical certainty is very low.
Adipocytes can expand up to 20 times their original volume.
"a fat cell can undergo more expansion than any other cell in the body that I'm aware of. It can get 20 times bigger than its original volume." (said at 1:35:50)
Adipocytes possess exceptional capacity for cellular expansion and hypertrophy. Biological reviews document that adipocytes can expand in volume by several hundred-fold to up to a thousand-fold during lipid accumulation and adipose tissue remodeling, easily encompassing a 20-fold increase in volume.
Dr. Roger Unger published papers demonstrating that inhibiting glucagon excess in type 1 diabetes corrects hyperglycemia without requiring insulin administration.
"Dr. Roger Unger at UT Southwestern over years published a series of mind-blowingly cool papers finding that in type 1 diabetes, if you just control the glucagon excess, you don't even need to give the patient insulin, that you could correct all hyperglycemia by just inhibiting the glucagon." (said at 2:00:00)
Dr. Roger Unger and colleagues at UT Southwestern published multiple landmark studies demonstrating that genetic deletion or monoclonal antibody blockade of the glucagon receptor prevented or normalized hyperglycemia and diabetic complications in completely insulin-deficient type 1 diabetic rodent models without the administration of insulin (e.g., Lee et al., 2011; Wang et al., 2015). Because these findings were established in rodent models, evidence evaluating insulin-free management in human type 1 diabetes remains strictly preclinical (graded very low certainty); human clinical trials using glucagon receptor antagonists (such as REMD-477) have demonstrated significant reductions in daily insulin requirements and improved glycemic control, rather than complete elimination of insulin therapy.
Hyperinsulinemia can be present and detectable decades before a person develops clinical hyperglycemia.
"But we know decades potentially before the person ever starts to have hyperglycemia, they have hyperinsulinemia." (said at 2:00:53)
Longitudinal cohort studies with decades of follow-up demonstrate that insulin resistance and compensatory hyperinsulinemia (elevated insulin secretion) precede the onset of clinical hyperglycemia and type 2 diabetes by 10 to 25 years while blood glucose concentrations remain within the normal range. For example, a 25-year prospective study of offspring of individuals with type 2 diabetes showed that marked insulin resistance and compensatory hyperinsulinemia were detectable more than a decade before diabetes developed in normoglycemic individuals. Similarly, long-term data from the Whitehall II prospective cohort demonstrated compensatory changes in insulin sensitivity and secretion up to 13 years prior to the diagnosis of diabetes, whereas marked increases in fasting and postprandial glucose occurred only in the 3 to 5 years immediately preceding diagnosis.
- supports: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results… (Lancet (London, England) 1992) · cited 1170x in the literature
"More than 10 years before the development of diabetes, subjects who developed the disease had lower values of both SI... Insulin secretion, especially first phase, tended to be increased rather than decreased in this prediabetic phase and was appropriate for the level of insulin resistance. The development of type 2 diabetes is preceded by and predicted by defects in both insulin-dependent and insulin-independent glucose uptake; the defects are detectable when the patients are normoglycaemic and in most cases more than a decade before diagnosis of disease." (abstract, results)
pubmedfull study (doi) - supports: Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of … (Lancet (London, England) 2009) · cited 902x in the literature
"In the diabetic group (801 measurements), a linear increase in fasting glucose was followed by a steep quadratic increase (from 5.79 mmol/L to 7.40 mmol/L) starting 3 years before diagnosis of diabetes. 2-h postload glucose showed a rapid increase starting 3 years before diagnosis... and HOMA insulin sensitivity decreased steeply during the 5 years before diagnosis... HOMA beta-cell function increased between years 4 and 3 before diagnosis... and then decreased until diagnosis" (abstract, results, passage verified)
pubmedfull study (doi)
Fat cells have an average lifespan of about 10 years.
"Now, however, a fat cell has a lifespan of about 10 years. And so, depending on the utility of that fat cell, it may not be replaced or it may be replaced." (said at 2:01:57)
Human retrospective carbon-14 dating studies demonstrate that human adipocytes turn over at a rate of approximately 10% per year across adulthood in both lean and obese individuals, corresponding to an average fat cell lifespan of approximately 10 years.
Fat cell count is largely determined during childhood and puberty, and adult weight gain in average individuals occurs primarily through hypertrophy rather than hyperplasia.
"during infancy, childhood, puberty, we're making fat cells. And then for the most part, the number of fat cells we have is set. Now women have a little buffer, like I said earlier, but even then you could have a person who gains 100 more pounds or 200 more pounds in adulthood. For the for the average individual, that's hypertrophy, not a result of hyperplasia." (said at 2:02:04)
Landmark research using retrospective 14C birth dating of adipocytes demonstrates that total fat cell number increases during childhood and adolescence and stabilizes in adulthood across both lean and obese individuals. In adults, fat mass changes are primarily driven by adipocyte hypertrophy (enlargement of existing cells via lipid storage) rather than substantial increases in total adipocyte count, although experimental overfeeding studies note that some lower-body subcutaneous depots can generate new adipocytes (hyperplasia) under specific conditions.
- supports: Dynamics of fat cell turnover in humans. (Nature 2008) · cited 2269x in the literature
"However, the number of fat cells stays constant in adulthood in lean and obese individuals, even after marked weight loss, indicating that the number of adipocytes is set during childhood and adolescence." (abstract, results, passage verified)
pubmedfull study (doi) - context: Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. (Proceedings of the National Academy of Sciences of the United States of America 2010) · cited 371x in the literature
"Average abdominal s.c. adipocyte size increased by 0.16 ± 0.06 μg lipid per cell and correlated with relative upper-body fat gain (r = 0.74, P < 0.0001). However, lower-body fat responded to overfeeding by fat-cell hyperplasia, with adipocyte number increasing by 2.6 ± 0.9 × 10(9) cells (P < 0.01)." (abstract, results, passage verified)
pubmedfull study (doi)
Studies show that removing substantial body fat via liposuction does not improve any cardiometabolic outcomes.
"And in fact, if you force artificial weight loss by sucking out fat cells where you are just sucking out the fat cells and reducing fat cell number, then you don't improve any cardiometabolic outcome whatsoever. So there's many studies that show that you can have people lose a significant amount of fat through liposuction, and there not a single outcome has improved." (said at 2:02:48)
The claim is supported by high-quality clinical trial evidence and meta-analyses. A landmark study published in the New England Journal of Medicine (PMID 15201411) evaluated the effect of large-volume abdominal liposuction (removing ~10 kg of fat) in women with abdominal obesity (both with and without type 2 diabetes) and found no significant improvements in liver, muscle, or adipose tissue insulin sensitivity, blood pressure, plasma glucose, lipid levels, or inflammatory markers (CRP, IL-6, TNF-alpha, adiponectin). A meta-analysis (PMID 23899478) similarly concluded that subcutaneous fat removal fails to reduce early cardiovascular or metabolic disease risk factors. While some smaller non-randomized studies report conflicting or isolated changes in specific markers (PMID 28737560), rigorous controlled trials confirm that surgical removal of subcutaneous fat alone does not deliver the cardiometabolic benefits associated with metabolic weight loss.
- supports: Absence of an effect of liposuction on insulin action and risk factors for coronary heart … (The New England journal of medicine 2004) · cited 905x in the literature
"Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor alpha, and adiponectin; and did not significantly affect other risk factors for coronary heart disease (blood pressure and plasma glucose, insulin, and lipid concentrations) in either group." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Suction-assisted lipectomy fails to improve cardiovascular metabolic markers of disease: a… (Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2013) · cited 30x in the literature
"Based on the results of our analysis, we conclude that there is no evidence to support the hypothesis that subcutaneous fat removal reduces early cardiovascular or metabolic disease, its markers or its risk factors." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Influence of Large-Volume Liposuction on Metabolic and Cardiovascular Health: A Systematic… (Annals of plastic surgery 2017) · cited 30x in the literature
"Current data, although conflicting, appear to support the notion that LVL can affect cardiovascular risk factors, metabolic balance, and insulin resistance in positive ways." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Ben Bikman's published case series documented the reversal of insulin resistance over 90 days in patients with type 2 diabetes.
"In fact, that's why with the slow insulin resistance, the reversal of that like over the 90 days in the type 2 diabetic patients that we had in our published case series, uh that would have been—not that we measured this, but it would have been because of a shrinking of the fat cell." (said at 2:04:29)
A published case series co-authored by Benjamin Bikman evaluated 11 adult female patients with recently diagnosed type 2 diabetes undergoing a 90-day ketogenic dietary intervention limiting carbohydrate intake to under 30 grams daily. Over 90 days, mean HbA1c decreased from 8.9% to 5.6%, returning levels to non-diabetic range, alongside significant body weight reduction (85.7 kg to 76.7 kg) and improvements in blood lipid markers of insulin resistance (such as a drop in the triglyceride-to-HDL ratio from 4.7 to 1.9). As an uncontrolled case series, this body of evidence is classified as very low certainty.
- supports: Improvement in Glycemic and Lipid Profiles in Type 2 Diabetics with a 90-Day Ketogenic Die… (Journal of diabetes research 2019) · cited 52x in the literature
"Because low-carbohydrate diets are effective strategies to improve insulin resistance, the hallmark of type 2 diabetes, the purpose of reporting these clinical cases was to reveal the meaningful changes observed in 90 days of low-carbohydrate (LC) ketogenic dietary intervention in female type 2 diabetics aged 18-45. Eleven women (BMI 36.3 kg/m 2 ) who were recently diagnosed with type 2 diabetes based on HbA1c over 6.5% (8.9%) volunteered to participate in an intensive dietary intervention to limit dietary carbohydrates to under 30 grams daily for 90 days... HbA1c dropped to 5.6%... These findings indicate that a short-term intervention emphasizing protein and fat at the expense of dietary carbohydrate functionally reversed the diabetes diagnosis, as defined by HbA1c." (abstract, background and results, passage verified)
pubmedfull study (doi)
Visceral adipocytes are more responsive to epinephrine-stimulated lipolysis than subcutaneous adipocytes.
"So visceral adipocytes are more responsive to the lipolytic signal, the fat breakdown signal of epinephrine. So, anything that increases epinephrine will have, sort of pound-for-pound or site-for-site, visceral versus subcutaneous is going to have a better visceral response." (said at 2:05:20)
Human ex vivo and metabolic studies demonstrate that visceral (e.g., omental and mesenteric) adipocytes have a higher lipolytic responsiveness and sensitivity to catecholamines (epinephrine and norepinephrine) than subcutaneous adipocytes. This regional variation is driven by greater lipolytic beta-adrenoceptor (beta-1, beta-2, and beta-3) expression/activity and lower antilipolytic alpha-2-adrenoceptor activity in visceral adipose tissue compared to subcutaneous depots, a difference that is particularly pronounced in individuals with central obesity.
- supports: Differences in lipolysis between human subcutaneous and omental adipose tissues. (Annals of medicine 1995) · cited 432x in the literature
"The rate of lipolysis is low in the subcutaneous femoral/gluteal region, intermediate in the subcutaneous abdominal region and high in the visceral (i.e. omental) region. In non-obese subjects the differences between the subcutaneous and visceral fat depots may be explained by site variations in the function of receptors for insulin, catecholamines and adenosine. The lipolytic beta 1 and beta 2 adrenoceptors, as well as the newly discovered beta 3, are most active in the visceral fat cells. The antilipolytic insulin receptors, alpha 2 adrenoceptors and adenosine receptors are most active in the subcutaneous fat cells." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocyte… (Journal of lipid research 1997) · cited 130x in the literature
"In contrast, catecholamine-induced lipolysis is markedly increased in omental as compared to subcutaneous adipocytes in obese males, mainly due to an increase in beta(3)-adrenoceptor function of visceral fat cells, in combination with a smaller increase in beta(1)-adrenoceptor function." (abstract, conclusions, passage verified)
pubmed - supports: Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocyte… (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1997) · cited 90x in the literature
"The noradrenaline-induced lipolytic response did not differ between omental and mesenteric adipocytes but was 50% higher than in subcutaneous adipocytes (P < 0.05). Furthermore, noradrenaline sensitivity and intrinsic activity (in relation to isoprenaline) were higher in the two visceral fat cells than in the subcutaneous fat cells." (abstract, results, passage verified)
pubmedfull study (doi)
A published study by K. Sreekumaran Nair's group found that insulin is not required for muscle protein synthesis, but serves primarily to inhibit muscle protein breakdown.
"So there was a group—in fact, I think it was the same guy I mentioned earlier, Nair at Minnesota at the time—they published a paper finding that insulin wasn't necessary for muscle protein synthesis... They documented that insulin was not necessary for muscle protein synthesis, but it was very helpful for inhibiting the breakdown. So they suggested that insulin's main effect on muscle is an antiproteolytic effect rather than a stimulating effect." (said at 2:07:15)
Studies conducted by K. Sreekumaran Nair's research group evaluated human muscle protein synthesis and breakdown in response to insulin infusions using stable isotope tracer methodologies. These clinical trials demonstrated that under postabsorptive conditions in adult humans, insulin does not significantly increase skeletal muscle protein synthesis, but instead exerts its anabolic/anticatabolic effect predominantly by suppressing muscle protein breakdown (proteolysis) in a dose-dependent manner.
Only a low concentration of insulin is required to inhibit muscle proteolysis.
"But it also didn't take a lot of insulin to inhibit the proteolysis." (said at 2:07:50)
Human forearm perfusion and tracer kinetic studies demonstrate that skeletal muscle proteolysis is exquisitely sensitive to insulin. Low physiological increments of plasma insulin (around 20 μU/ml above basal) achieve maximal or near-maximal suppression of muscle protein breakdown (approximately 38-40%), with higher insulin doses providing no substantial additional antiproteolytic effect.
- supports: Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. (The Journal of clinical investigation 1992) · cited 170x in the literature
"Phenylalanine and leucine R(a) declined by approximately 38 and 40% with the lowest dose insulin infusion. Higher doses of insulin produced no greater effect (decline in R(a) varied between 26 and 42% for phenylalanine and 30-50% for leucine). In contrast, R(d) for phenylalanine and leucine did not change with insulin. We conclude that even modest increases of plasma insulin can markedly suppress proteolysis, measured by phenylalanine R(a), in human forearm skeletal muscle." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin's anti… (Diabetes 1992) · cited 93x in the literature
"For the last 3 h of the GH infusion, insulin was coinfused with a dose that, in the absence of infused GH, suppressed forearm muscle proteolysis by 30-40% without affecting systemic insulin levels." (abstract, results, passage verified)
pubmedfull study (doi)
At low antidiabetic doses, GLP-1 receptor activators act by inhibiting pancreatic alpha cells and suppressing glucagon secretion.
"So at the lower dose originally used, these GLP-1 activators worked actually by inhibiting glucagon. So back to the alpha cell that I mentioned earlier, we come back to them now, where in type 2 diabetes, the insulin resistance of the alpha cell results in a chronic elevation of glucagon, chronically then telling the liver to be releasing glucose, leading to the hyperglycemia that defines the diabetic state. At this low dose, semaglutide inhibits the alpha cell. It inhibits glucagon, and by inhibiting glucagon, you're helping correct blood glucose." (said at 2:11:40)
GLP-1 receptor agonists (including semaglutide at standard antidiabetic doses) lower blood glucose through complementary mechanisms that include glucose-dependent stimulation of insulin secretion from beta cells and suppression of glucagon secretion from pancreatic alpha cells, which in turn reduces hepatic glucose output. Randomized, double-blind clinical trials in patients with type 2 diabetes demonstrate that therapeutic doses of semaglutide significantly reduce fasting, postprandial, and 24-hour glucagon levels alongside improving glycemic control.
- supports: Effects of semaglutide on beta cell function and glycaemic control in participants with ty… (Diabetologia 2017) · cited 115x in the literature
"The 24 h meal test showed reduced fasting, postprandial and overall (AUC 0-24h ) glucose and glucagon responses with semaglutide (p < 0.0001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric em… (Diabetes, obesity & metabolism 2021) · cited 83x in the literature
"Postprandial glucose (AUC 0-5h ) was significantly lower with oral semaglutide versus placebo (estimated treatment ratio, 0.71; 95% CI, 0.63, 0.81; p < .0001); glucose incremental AUC (iAUC 0-5h/5h ) and glucagon AUC 0-5h were also significantly reduced, with similar results after the fat-rich breakfast." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus an… (International journal of molecular sciences 2022) · cited 58x in the literature
"Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue." (abstract, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonists delay gastric emptying and slow intestinal peristalsis in humans.
"Within the intestines, GLP-1 will act to delay gastric emptying and slow peristalsis. So that has the effect of a person eating and having that bulk sit in their stomach much longer, which is going to generally discourage them from wanting to eat more." (said at 2:12:55)
Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists inhibit upper gastrointestinal motility in humans, measurably delaying gastric emptying and slowing small-bowel intestinal transit. A systematic review and meta-analysis of clinical trials found that GLP-1 receptor agonists significantly delayed gastric emptying half-time (T1/2) on scintigraphy by a pooled mean difference of 36.0 minutes compared to placebo. In addition, prospective human clinical studies demonstrate that GLP-1-based therapies significantly prolong small-bowel transit time.
- supports: Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A System… (The American journal of gastroenterology 2024) · cited 86x in the literature
"Mean T 1/2 was 138.4 minutes (95% CI 74.5-202.3) for GLP-1 RA vs 95.0 minutes (95% CI 54.9-135.0) for placebo, with a pooled mean difference of 36.0 minutes (95% CI 17.0-55.0, P < 0.01, I2 = 79.4%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Association between GLP-1-based therapy and small-bowel transit time during capsule endosc… (BMJ open gastroenterology 2026)
"In multivariable linear regression restricted to examinations with calculable small-bowel transit time and complete covariate data, GLP-1-based therapy was independently associated with longer small-bowel transit time after adjustment for age, body mass index, diabetes mellitus and indication for capsule endoscopy (adjusted β+83 min, 95% CI 3.1 to 162.8; p=0.042)." (abstract, results, passage verified)
pubmedfull study (doi)
A 1996 study published in Gut found that while lean and obese individuals had similar GLP-1 responses to a high-fat meal, obese individuals exhibited no statistically significant GLP-1 increase after a high-carbohydrate meal.
"A paper was published in 1996 that looked at the changes in GLP-1 in two populations. They took otherwise healthy humans and split them up, and they noticed changes in the obese group and the lean group. So when they gave both groups a high-fat meal, they looked at the GLP-1 response, and it was roughly similar in both groups... However, when they gave them a high-carb meal, the lean group had a huge increase in GLP-1. The obese group had no statistically significant response whatsoever... It was published in the journal Gut in 1996." (said at 2:17:17)
A 1996 physiological study published in Gut (Ranganath et al.) compared GLP-1 responses to carbohydrate and fat meals in 6 obese and 6 matched lean women. The authors found that while GLP-1 secretion in response to an oral fat meal did not differ between the two groups, GLP-1 secretion after an oral carbohydrate meal was markedly attenuated in the obese subjects compared to lean controls.
A clinical trial published in the New England Journal of Medicine found that approximately 40% of the total weight lost on semaglutide was lean/fat-free mass.
"The evidence is very real showing—one of the best-looked papers in the New England Journal of Medicine about two, three years ago found that about almost 40% of the weight loss that a person was losing was fat-free mass. Now, that is itself a big pool, but some of it would be muscle and bone mass." (said at 2:24:30)
The claim accurately reflects the body composition sub-study findings of the STEP 1 trial, published in The New England Journal of Medicine (Wilding et al., 2021). In this randomized controlled trial of 1,961 adults with overweight or obesity, 68 weeks of once-weekly semaglutide 2.4 mg combined with lifestyle intervention led to a mean body weight loss of 14.9%. In the exploratory dual-energy X-ray absorptiometry (DEXA) body composition sub-study, fat-free mass loss accounted for approximately 39% (nearly 40%) of the total weight loss, while fat mass reduction accounted for the remaining ~61%.
Approximately 70% of Americans prescribed GLP-1 agonist medications discontinue taking the drug within two years.
"And in fact, 70% in the US, 70% of Americans get off the drug at 2 years either because of cost or nausea or whatever, 70% stop taking it." (said at 2:33:39)
Real-world observational studies and pharmacy claims analyses in the United States show that approximately 60% to 70% of patients discontinue GLP-1 receptor agonist therapy within two years. In cohorts of patients with type 2 diabetes or obesity, persistence drops significantly over time, with real-world discontinuation rates reaching roughly 64% to 70% by 24 months. Common reasons for discontinuation include gastrointestinal side effects (such as nausea and vomiting), high out-of-pocket costs, loss of insurance coverage, and medication supply shortages.
- supports: Causes and consequences of discontinuation of GLP1RAs or tirzepatide. (Nature reviews. Endocrinology 2026) · cited 4x in the literature
"Reasons for treatment discontinuation include, but are not limited to, gastrointestinal adverse effects, less-than-desired efficacy, high cost, and fear about uncommon or rare adverse effects." (abstract, passage verified)
pubmedfull study (doi) - supports: Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrat… (Current diabetes reports 2026)
"Persistence generally declined over time and often fell below 60% by 12 to 24 months, although estimates varied by refill-gap definitions and analytic approaches. Discontinuation reached 64.1% at 2 years in one large cohort, and treatment interruption with reinitiation was common." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Predicting GLP-1 Discontinuation From Pharmacy Claims. (The American journal of managed care 2026)
"Yet multiple real-world studies show that adherence and persistence are modest: In obesity cohorts without diabetes, approximately one-third of members remain on therapy at 1 year, and among those with type 2 diabetes, nearly half discontinue by 12 months and approximately 70% by 24 months." (abstract, passage verified)
pubmedfull study (doi)
A study published within the past year found that people on standard Wegovy dosing for up to two years had double the risk of suicidal behavior, triple the risk of major depression, and a 106% increased risk of anxiety.
"a paper was published within the past six months, I think it was within the past six months, definitely within the past year, the risk of suicidal behavior doubles and the risk of major depression triples in people who were on the drug for up to two years... the major depression risk, people were three times more likely to have clinically diagnosed major depression. And again, twice more likely for suicidal behavior and twice as likely, it was like 106% increased risk of anxiety." (said at 2:33:59)
A retrospective cohort study published in October 2024 in Scientific Reports (PMID: 39424950) evaluated post-marketing electronic health records of patients with obesity prescribed GLP-1 receptor agonists (semaglutide and liraglutide) compared to matched controls. The authors reported that GLP-1 RA use was associated with a 195% higher risk of major depression (almost triple), a 108% increased risk of anxiety, and a 106% elevated risk of suicidal behavior (roughly double). However, this evidence comes from observational real-world data subject to residual confounding; subsequent systematic reviews and meta-analyses of randomized trials and active-comparator cohorts have generally found no statistically significant increases in depression, anxiety, or suicidal behaviors associated with semaglutide.
- supports: The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucago… (Scientific reports 2024) · cited 123x in the literature
"Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior." (abstract, results, passage verified)
pubmedfull study (doi) - context: Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and M… (Clinical obesity 2026)
"The pooled risk ratio for depression was 1.25 (95% CI: 0.95-1.65; I 2 = 98%). For anxiety and suicidal ideation/attempt, pooled risk ratios were 1.22 (95% CI: 0.93-1.60; I 2 = 99%) and 1.20 (95% CI: 0.90-1.62; I 2 = 92%), respectively. No statistically significant differences were observed between semaglutide and comparator/placebo groups for outcomes." (abstract, results, passage verified)
pubmedfull study (doi)
The AMORIS study from Sweden demonstrated that uric acid levels and blood glucose control were predictive biomarkers of longevity.
"that really well-done longevity study, the AMORIS study from Sweden, found that uric acid was one of the very few predictors that when they looked retrospectively at these people measuring the same markers for decades, their glucose control was a predictive variable and their uric acid was a predictive variable as to who lived the longest, healthiest lives." (said at 2:40:42)
A 35-year follow-up study of the Swedish AMORIS cohort published in GeroScience (Murata et al., 2024) investigated blood biomarker profiles measured between ages 64 and 99 in relation to exceptional longevity (reaching age 100). The analysis of 1,224 centenarians compared to shorter-lived peers demonstrated that lower blood glucose and lower uric acid levels (along with lower creatinine, liver enzymes, and higher total cholesterol and iron) were significantly associated with the chance of reaching 100 years of age.
Advanced glycation end-products (AGEs) bind to and activate the receptor for advanced glycation end-products (RAGE), triggering inflammatory cascades.
"when you form an advanced glycation end-product, it becomes a ligand for RAGE, the receptor for advanced glycation end-products. And when RAGE gets activated, you have a lot of inflammation." (said at 2:42:01)
Advanced glycation end-products (AGEs) serve as ligands that bind to the receptor for advanced glycation end-products (RAGE). Binding and activation of RAGE stimulate downstream intracellular signaling pathways, such as NF-κB and MAPKs, which drive pro-inflammatory gene expression, cytokine production, and oxidative stress across metabolic, vascular, and inflammatory disease states.
- supports: Receptor for Advanced Glycation End Products (RAGE) Ligand Axis as a Mediator of Inflammat… (Current pharmaceutical design 2026)
"Once expressed, RAGE interacts with seemingly unrelated ligands, such as AGE, HMGB1, S100, and others, and the RAGE-ligand(s) axis triggers inflammation and oxidative stress and sustains a vicious cycle of self-propagation." (abstract, passage verified)
pubmedfull study (doi) - supports: The AGE-RAGE-DIAPH1 Axis in Type 2 Diabetes and Metabolic Dysfunction: From Carbonyl Stres… (International journal of molecular sciences 2026)
"Across experimental models, this signaling axis promotes oxidative stress and inflammatory activation, leading to endothelial dysfunction and barrier failure." (abstract, passage verified)
pubmedfull study (doi) - supports: RAGE Signalling in Acute Inflammatory Disorders: Therapeutic Potential of Natural Products… (Biomolecules 2026)
"The receptor for advanced glycation end-products (RAGE) serves as a pivotal multi-ligand pattern recognition receptor that integrates PAMPs and DAMPs. Excessive RAGE engagement triggers detrimental signalling cascades, notably NF-κB and MAPKs, which exacerbate hyperinflammation and lead to progressive organ dysfunction." (abstract, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications
No PubMed publication profile has been built for this speaker yet.